NCT02074995View on ClinicalTrials.gov

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Hypercatabolic Status Related to Severe Burn
Interventions
BIOLOGICAL

BVS857

Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

OTHER

placebo

Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

Trial Locations (1)

27157

Novartis Investigative Site, Winston-Salem

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY